Clinical evaluation of cinnarizine in patients with cerebral circulatory deficiency.
D000368:Aged; D000437:Alcoholism / Q000188:drug therapy; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002934:Cinnamates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010919:Placebos; D011594:Psychometrics; D011618:Psychotic Disorders / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy; D014665:Vasodilator Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D002934:Cinnamates; D010879:Piperazines; D010919:Placebos; D014665:Vasodilator Agents